EyePoint, Inc. (NASDAQ: EYPT) announced topline results from LUGANO, the first of two pivotal Phase 3 clinical trials evaluating DURAVYU ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE